ESR1 and breast cancer: Addition of an IGF-IR/InsR tyrosine kinase inhibitor (TKI) enhanced the action of AZD5363 against MCF-7 xenografts in ovariectomized mice devoid of estrogen supplementation, suggesting a novel and testable therapeutic combination for patients with ER+ breast cancer.